Sponsor

The University Of Birmingham

United Kingdom Vincent Drive, B15 2TT, United Kingdom

About the sponsor

Clinical research includes acute myeloid leukaemia, high-risk myelodysplastic syndrome, isolated myeloid sarcoma, polycythaemia vera, and mature B-cell non-Hodgkin lymphoma, with interest in relapsed, refractory, and newly diagnosed disease.

Acute myeloid leukaemia
Myelodysplastic syndrome
Polycythaemia vera
B-cell non-Hodgkin lymphoma

Work in this area spans systemic treatment strategies, targeted therapy, and stem cell transplant-related care.

About Specializations

The University Of Birmingham runs clinical trials in conditions such as Neuroblastoma, Rhabdomyosarcoma, Acute myeloid leukaemia, Germ cell cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

13 clinical trials

Neuroblastoma+2

Recruiting

Indocyanine Green and Near-Infrared Fluorescence for Lymph Node Removal in Children with Renal Tumours or Paratesticular Rhabdomyosarcoma

Registered drugNo placebo

Indocyanine Green and Near-Infrared Fluorescence for Lymph Node Removal in Children with Renal Tumours or Paratesticular Rhabdomyosarcoma

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Indocyanine Green
Sponsor:The University Of Birmingham

Contact Research Centre

B-cell lymphoma recurrent+1

Recruiting

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Bevacizumab
Sponsor:The University Of Birmingham

Contact Research Centre

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Extra-osseous Ewing's sarcoma+5

Recruiting

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Docetaxel
Sponsor:The University Of Birmingham

Contact Research Centre

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Polycythaemia vera

Recruiting

Comparison of ruxolitinib versus hydroxycarbamide or interferon alfa as first treatment for high-risk polycythemia vera patients

Registered drugNo placebo

Comparison of ruxolitinib versus hydroxycarbamide or interferon alfa as first treatment for high-risk polycythemia vera patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Hydroxycarbamide
Sponsor:The University Of Birmingham

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:The University Of Birmingham

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia

Registered drugNo placebo

Study comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:The University Of Birmingham

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma

Registered drugNo placebo

Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma

Registered drugNo placebo

France

Participants:0–17 years
Substances:Busulfan
Sponsor:The University Of Birmingham

Contact Research Centre

Oropharyngeal cancer

Not recruiting

Study of Cisplatin, Carboplatin and Durvalumab Treatment for Patients with Intermediate and High-Risk Oropharyngeal Cancer

Registered drugNo placebo

Study of Cisplatin, Carboplatin and Durvalumab Treatment for Patients with Intermediate and High-Risk Oropharyngeal Cancer

Registered drugNo placebo

Ireland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Colorectal cancer

Not recruiting

Study of organ preservation using chemoradiotherapy and transanal surgery compared to standard surgery in patients with early rectal cancer (STAR-TREC trial)

Registered drugNo placebo